Also known as: Senseonics
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.
Sequel Med Tech and Senseonics announced full U.S. availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM, the world's only one-year continuous glucose monitor, for people with type 1 diabetes.
